Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timeline The designation is supported by a Phase 2 study in which nipocalimab demonstrated reduction in lupus disease activity and potential for steroid sparing...
Hence then, the article about johnson johnson therapy nipocalimab granted u s fda fast track designation in systemic lupus erythematosus sle was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE) )
Also on site :
- Trump dismisses criticism from Megyn Kelly and Tucker Carlson over Iran attacks: ‘MAGA loves what I’m doing’
- Epstein deposition videos show Hillary Clinton in heated moments with lawmakers, Bill Clinton addressing hot tub photo
- Shareholder Alert: The Ademi Firm investigates whether Select Medical Holdings Corporation is obtaining a Fair Price for its Public Shareholders